Cato M Drion1, Lars E Borm1, Lieneke Kooijman1, Eleonora Aronica2,3, Wytse J Wadman1, Aloysius F Hartog4, Erwin A van Vliet2, Jan A Gorter1. 1. Center for Neuroscience, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands. 2. Department (Neuro)Pathology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. 3. Epilepsy Institute in the Netherlands, Heemstede, The Netherlands. 4. Van't Hoff Institute for Molecular Sciences, University of Amsterdam, Amsterdam, The Netherlands.
Abstract
OBJECTIVE: Inhibition of the mammalian target of rapamycin (mTOR) pathway has been suggested as a possible antiepileptogenic strategy in temporal lobe epilepsy (TLE). Here we aim to elucidate whether mTOR inhibition has antiepileptogenic and/or antiseizure effects using different treatment strategies in the electrogenic post-status epilepticus (SE) rat model. METHODS: Effects of mTOR inhibitor rapamycin were tested using the following three treatment protocols: (1) "stop-treatment"-post-SE treatment (6 mg/kg/day) was discontinued after 3 weeks; rats were monitored for 5 more weeks thereafter, (2) "pretreatment"-rapamycin (3 mg/kg/day) was applied during 3 days preceding SE; and (3) "chronic phase-treatment"-5 days rapamycin treatment (3 mg/kg/day) in the chronic phase. We also tested curcumin, an alternative mTOR inhibitor with antiinflammatory and antioxidant effects, using chronic phase treatment. Seizures were continuously monitored using video-electroencephalography (EEG) recordings; mossy fiber sprouting, cell death, and inflammation were studied using immunohistochemistry. Blood was withdrawn regularly to assess rapamycin and curcumin levels with high performance liquid chromatography (HPLC). RESULTS: Stop-treatment led to a strong reduction of seizures during the 3-week treatment and a gradual reappearance of seizures during the following 5 weeks. Three days pretreatment did not prevent seizure development, whereas 5-day rapamycin treatment in the chronic phase reduced seizure frequency. Washout of rapamycin was slow and associated with a gradual reappearance of seizures. Rapamycin treatment (both 3 and 6 mg/kg) led to body growth reduction. Curcumin treatment did not reduce seizure frequency or lead to a decrease in body weight. SIGNIFICANCE: The present study indicates that rapamycin cannot prevent epilepsy in the electrical stimulation post-SE rat model but has seizure-suppressing properties as long as rapamycin blood levels are sufficiently high. Oral curcumin treatment had no effect on chronic seizures, possibly because it did not reach the brain at adequate levels. Wiley Periodicals, Inc.
OBJECTIVE: Inhibition of the mammalian target of rapamycin (mTOR) pathway has been suggested as a possible antiepileptogenic strategy in temporal lobe epilepsy (TLE). Here we aim to elucidate whether mTOR inhibition has antiepileptogenic and/or antiseizure effects using different treatment strategies in the electrogenic post-status epilepticus (SE) rat model. METHODS: Effects of mTOR inhibitor rapamycin were tested using the following three treatment protocols: (1) "stop-treatment"-post-SE treatment (6 mg/kg/day) was discontinued after 3 weeks; rats were monitored for 5 more weeks thereafter, (2) "pretreatment"-rapamycin (3 mg/kg/day) was applied during 3 days preceding SE; and (3) "chronic phase-treatment"-5 days rapamycin treatment (3 mg/kg/day) in the chronic phase. We also tested curcumin, an alternative mTOR inhibitor with antiinflammatory and antioxidant effects, using chronic phase treatment. Seizures were continuously monitored using video-electroencephalography (EEG) recordings; mossy fiber sprouting, cell death, and inflammation were studied using immunohistochemistry. Blood was withdrawn regularly to assess rapamycin and curcumin levels with high performance liquid chromatography (HPLC). RESULTS: Stop-treatment led to a strong reduction of seizures during the 3-week treatment and a gradual reappearance of seizures during the following 5 weeks. Three days pretreatment did not prevent seizure development, whereas 5-day rapamycin treatment in the chronic phase reduced seizure frequency. Washout of rapamycin was slow and associated with a gradual reappearance of seizures. Rapamycin treatment (both 3 and 6 mg/kg) led to body growth reduction. Curcumin treatment did not reduce seizure frequency or lead to a decrease in body weight. SIGNIFICANCE: The present study indicates that rapamycin cannot prevent epilepsy in the electrical stimulation post-SE rat model but has seizure-suppressing properties as long as rapamycin blood levels are sufficiently high. Oral curcumin treatment had no effect on chronic seizures, possibly because it did not reach the brain at adequate levels. Wiley Periodicals, Inc.
Authors: Fernando Lopes; Åsa V Keita; Alpana Saxena; Jose Luis Reyes; Nicole L Mancini; Ala Al Rajabi; Arthur Wang; Cristiane H Baggio; Michael Dicay; Rob van Dalen; Younghee Ahn; Matheus B H Carneiro; Nathan C Peters; Jong M Rho; Wallace K MacNaughton; Stephen E Girardin; Humberto Jijon; Dana J Philpott; Johan D Söderholm; Derek M McKay Journal: J Biol Chem Date: 2018-01-09 Impact factor: 5.157
Authors: Eleonora Aronica; Sebastian Bauer; Yuri Bozzi; Matteo Caleo; Raymond Dingledine; Jan A Gorter; David C Henshall; Daniela Kaufer; Sookyong Koh; Wolfgang Löscher; Jean-Pierre Louboutin; Michele Mishto; Braxton A Norwood; Eleonora Palma; Michael O Poulter; Gaetano Terrone; Annamaria Vezzani; Rafal M Kaminski Journal: Epilepsia Date: 2017-07 Impact factor: 5.864
Authors: Melissa Barker-Haliski; Kevin Knox; Dannielle Zierath; Zachery Koneval; Cameron Metcalf; Karen S Wilcox; H Steve White Journal: Epilepsia Date: 2021-06-02 Impact factor: 6.740
Authors: Christina Schmitt; Anna Lechanteur; François Cossais; Coralie Bellefroid; Philipp Arnold; Ralph Lucius; Janka Held-Feindt; Geraldine Piel; Kirsten Hattermann Journal: Int J Nanomedicine Date: 2020-05-25
Authors: Pavel Klein; Raymond Dingledine; Eleonora Aronica; Christophe Bernard; Ingmar Blümcke; Detlev Boison; Martin J Brodie; Amy R Brooks-Kayal; Jerome Engel; Patrick A Forcelli; Lawrence J Hirsch; Rafal M Kaminski; Henrik Klitgaard; Katja Kobow; Daniel H Lowenstein; Phillip L Pearl; Asla Pitkänen; Noora Puhakka; Michael A Rogawski; Dieter Schmidt; Matti Sillanpää; Robert S Sloviter; Christian Steinhäuser; Annamaria Vezzani; Matthew C Walker; Wolfgang Löscher Journal: Epilepsia Date: 2017-12-15 Impact factor: 5.864